期刊
LEUKEMIA RESEARCH
卷 31, 期 10, 页码 1441-1444出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2007.02.004
关键词
chronic myelogenous leukemia; blastic phase; 12-0-tetradecanoylphorbol-13-acetate; imatinib; resistant
We have demonstrated that 12-0-tetradecanoylphorbol-13-acetate (TPA) combined with vitamin D-3 (VD3) and cytosine arabinoside (Ara C) is effective and feasible for chronic myelogenous leukemia (CML) in blastic phase (BP). In the current study, the efficacy of TPA combined with inhibitor imatinib mesylate (imatinib) was investigated in patients with CML in BP that was resistant to standard-dose imatinib (400 mg/day). The results suggested that TPA combined with imatinib (400 mg/day) might overcome disease-poor response to conventional doses. So this approach deserves further evaluation as frontline therapy for newly diagnosed CML. (c) 2007 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据